Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10373321" target="_blank" >RIV/00216208:11110/18:10373321 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1111/apt.14539" target="_blank" >https://doi.org/10.1111/apt.14539</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/apt.14539" target="_blank" >10.1111/apt.14539</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus

Popis výsledku v původním jazyce

In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. To update the consensus with new evidence. A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previosly developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus. A total of 70 studies were included (IBS, 34; diarrhoea ssociated with antibiotics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other conditions, 16). Of 15 studies that examined global IBS symptoms as a primary endpoint, 8 reported significant benefits of probiotics vs placebo. Consensus statements with 100% agreement and &quot;high&quot; evidence level indicated that specific probiotics help reduce overall symptom burden and abdominal pain in some patients with IBS and duration/intensity of diarrhoea in patients prescribed antibiotic or H. pylori eradication therapy, and have favourable safety. Statements with 70%-100% agreement and &quot;moderate&quot; evidentce indicated that, in some patients with IBS, specific probiotics help reduce bloating/distension and improve bowel movement frequency/consistency. This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publication did not report benefits of probiotic, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety. This study will help clinicians recommend/prescribe probiotics for specific symptoms.

Název v anglickém jazyce

Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus

Popis výsledku anglicky

In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. To update the consensus with new evidence. A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previosly developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus. A total of 70 studies were included (IBS, 34; diarrhoea ssociated with antibiotics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other conditions, 16). Of 15 studies that examined global IBS symptoms as a primary endpoint, 8 reported significant benefits of probiotics vs placebo. Consensus statements with 100% agreement and &quot;high&quot; evidence level indicated that specific probiotics help reduce overall symptom burden and abdominal pain in some patients with IBS and duration/intensity of diarrhoea in patients prescribed antibiotic or H. pylori eradication therapy, and have favourable safety. Statements with 70%-100% agreement and &quot;moderate&quot; evidentce indicated that, in some patients with IBS, specific probiotics help reduce bloating/distension and improve bowel movement frequency/consistency. This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publication did not report benefits of probiotic, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety. This study will help clinicians recommend/prescribe probiotics for specific symptoms.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Alimentary Pharmacology &amp; Therapeutics

ISSN

0269-2813

e-ISSN

—

Svazek periodika

47

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

17

Strana od-do

1054-1070

Kód UT WoS článku

000428308500001

EID výsledku v databázi Scopus

2-s2.0-85042149123